Status | Study |
Not yet recruiting |
Study Name: Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts Condition: B-Cell Acute Lymphoblastic Leukemia, Adult Date: 2017-05-16 Interventions: Drug: blinatumomab |
Recruiting |
Study Name: The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). Condition: B-cell Acute Lymphoblastic Leukemia Date: 2016-09-29 Interventions: Drug: Cyclophosphamide patient |
Recruiting |
Study Name: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults Condition: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia Date: 2015-11-25 |
Withdrawn |
Study Name: Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL Condition: CD22+ Relapsed/Refractory B-ALL Date: 2015-11-13 Interventions: Drug: 90Y-epratuzumab tetraxetan |
Recruiting |
Study Name: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Condition: B-cell Acute Lymphoblastic Leukemia Relapsed Date: 2014-08-26 Interventions: Biological: CTL019 T-cells Other Name: CART19 |
Withdrawn |
Study Name: Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Condition: Relapsed or Refractory Acute Myeloid Leukemia Relapsed or Refractory B Date: 2014-08-07 Interventions: Drug: VS-4718 |
Recruiting |
Study Name: Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O) Condition: Leukemia Date: 2014-07-22 Interventions: Drug: Ofatumumab 300 mg by vei |
Withdrawn |
Study Name: Study of Efficacy and Safety of CTL019 in Adult ALL Patients Condition: B-cell Acute Lymphoblastic Leukemia Relapsed Date: 2014-06-17 Interventions: Drug: CTL019 A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 |
Active, not recruiting |
Study Name: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Condition: Relapsed B-Cell Acute Lymphoblastic Leukemia Date: 2013-05-21 Interventions: Procedure: leukapheresis or collection of PBMCs |
Completed |
Study Name: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults Condition: Burkitt's Lymphoma High-grade B-cell Lymphoma Date: 2013-03-08 Interventions: Other: No intervention (observational study) |